ProCE Banner Activity

Phase III CLL14: Venetoclax + Obinutuzumab vs Chlorambucil + Obinutuzumab in Patients With Previously Untreated CLL and Comorbidities

Slideset Download
Conference Coverage
Venetoclax/obinutuzumab produced significantly longer PFS and higher MRD negativity rates compared with chlorambucil/obinutuzumab in patients with previously untreated CLL and comorbidities.

Released: June 10, 2019

Expiration: June 08, 2020

Share

Provided by

Provided by the USF Health
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Astellas Seattle Genetics

Bayer Healthcare Pharma

Blueprint Medicines

Celgene

Novartis Pharmaceuticals Corporation

Puma Biotechnology, Inc.

Taiho Oncology Inc

Tesaro